Navigation Links
OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017
Date:10/25/2013

Rockville, MD (PRWEB) October 25, 2013

OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017

The level of unmet needs for NASH, including both environmental and clinical, is high and includes patient awareness, physician education, and approved therapies specific to NASH. These issues compound the reasons why the NASH market space is very sparse. A series of unknowns exist for the disease, due to its heterogeneous nature, and its slow progression poses problems for drug development.

Vitamin E, the current goldstandard therapy, dominates what little drug therapy NASH market there is. We expect Genfit’s small molecule GFT505 to claim patient share within the diabetic subpopulation, and Intercept Pharmaceuticals/DSP’s small molecule OCA to claim patients in all subpopulations, thus giving it an advantage. These products will likely solve the top unmet need - the dire need for an approved therapy for NASH.

The growing global rate of obesity and diabetes will boost the NASH market from $233 million in 2012 to $863 million by 2017, at a significant CAGR of 30%. The US will have the largest share of the market, contributing $827 million towards global sales, followed by the five major European markets - France, Germany, Italy, Spain and the UK. Currently, there are 29.3 million prevalent cases of NASH across these six major markets.

Dina Rufo, MS, GlobalData's Analyst covering Immunology, says: “Since there is neither cure, nor one specific therapy currently available for NASH, R&D strategies in this market space are complicated. Challenges range from unraveling the pathophysiology of NASH and designing diagnostic tools for more accurate diagnosis and staging, to the design of clinical trials. Furthermore, the level of unmet needs for NASH, including both environmental and clinical, is high and requires patient awareness and physician education."

To order this report:

OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017

Contact: Shauna
800.298.5699
Customerservice(at)marketresearch(dot)com

GlobalData

GlobalData is the premier source of actionable insight into the energy and healthcare industries. With the combined expertise of more than 1,000 researchers, market analysts and consultants, we provide high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

About MarketResearch.com

MarketResearch.com is the leading provider of global market intelligence products and services. With research reports from more than 720 top consulting and advisory firms, MarketResearch.com offers instant online access to the world’s most extensive database of expert insights on global industries, companies, products, and trends. Moreover, MarketResearch.com’s Research Specialists have in-depth knowledge of the publishers and the various types of reports in their respective industries and are ready to provide research assistance. For more information, call Cindy Frei at 240.747.3014 or visit http://www.marketresearch.com

Follow us on Facebook http://www.facebook.com/marketresearchdotcom
Follow us on Twitter http://www.twitter.com/marketresearch_

OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 – Table of Contents:

1 Table of Contents
2 Introduction
3 Disease Overview
4 Epidemiology
5 Current Treatment Options
6 Unmet Needs Assessment and Opportunity Analysis
7 R&D Strategies
8 Pipeline Assessment
9 Pipeline Valuation Analysis
10 Appendix
1.1 List of Tables
Table 1: Symptoms of NASH
Table 2: Risk Factors and Comorbidities for NASH
Table 3: Reported Prevalence of NASH in the US and 5EU
Table 4: Reported Prevalence of NAFLD in the US and 5EU
Table 5: 6MM, Sources of Prevalence Data Used in the NASH Epidemiological Forecast
Table 6: 6MM, Prevalent Cases of NASH, Ages = 20 Years, Men and Women, N, Selected Years, 2012-2022
Table 7: 6MM, Prevalent Cases of NASH, By Age*, Men and Women, N (Row %), 2012
Table 8: 6MM, Prevalent Cases of NASH, Ages = 20 Years, By Sex, N (Row %), 2012
Table 9: Off-Label Treatments for NASH
Table 10: Product Profile - Vitamin E
Table 11: Vitamin E SWOT Analysis in NASH, 2013
Table 12: Product Profile - Pioglitazone
Table 13: Pioglitazone SWOT Analysis in NASH, 2013
Table 14: Overall Unmet Needs in NASH - Current Level of Attainment
Table 15: Current Clinical Trial Design of Key Pipeline Drugs for NASH, 2013
Table 16: NASH - Mid-Late-Stage Pipeline, 2013
Table 17: Product Profile - GFT505
Table 18: GFT505 SWOT Analysis, 2013
Table 19: Product Profile - Obeticholic Acid (INT-747)
Table 20: Obeticholic Acid (INT-747) SWOT Analysis, 2013
Table 21: Product Profile - Simtuzumab
Table 22: Simtuzumab SWOT Analysis, 2013
Table 23: Product Profile - Liraglutide
Table 24: Liraglutide Safety Profile from the LEAD Program
Table 25: Liraglutide SWOT Analysis, 2013
Table 26: Early-Stage Pipeline Products in NASH, 2013
Table 27: Clinical Benchmark of Key Pipeline Drugs for NASH, 2013
Table 28: Commercial Benchmark of Key Pipeline Drugs for NASH, 2013
Table 29: Top-Line Sales Forecasts ($m) for NASH, 2012-2017
Table 30: Key Events Impacting Sales for NASH, 2017
Table 31: NASH Market: US and 5EU - Drivers and Barriers, 2012-2017
Table 32: Key Launch Dates
1.2 List of Figures
Figure 1: Two-Hit and Multiple-Hits Theories in NASH
Figure 2: Distinct-Hit Pathogenesis in NASH
Figure 3: Stages of Liver Disease
Figure 4: 5EU, Prevalence of NAFLD and Obesity, Ages = 20 Years, Men and Women, %
Figure 5: 6MM, Prevalent Cases of NASH, Ages = 20 Years, Men and Women, N, Selected Years, 2012-2022
Figure 6: 6MM, Prevalent Cases of NASH, By Age*, Men and Women, N, 2012
Figure 7: 6MM, Prevalent Cases of NASH, Ages = 20 Years, By Sex, N, 2012
Figure 8: Liver Biopsy to Confirm NASH
Figure 9: Competitive Assessment of Mid-Stage Pipeline Agents in NASH, 2012-2017
Figure 10: Competitive Assessment of Mid-Stage Pipeline Agents in NASH, 2012-2017
Figure 11: Global Sales for NASH by Region, 2012-2017

Read the full story at http://www.prweb.com/releases/2013/10/prweb11252212.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Dietary medium chain triglycerides prevent nonalcoholic fatty liver disease
2. Nonalcoholic Red Wine Might Help Lower Blood Pressure
3. HealthPostures and Electronic Office Environments to Attend National Minority Supplier Development Council Conference and Business Opportunity Fair
4. Pharmaceutical Insiders with Proof of Company’s Improper Relationships: Federal Law Offers Whistleblowers Opportunity for Sizable Financial Compensation, Parker Waichman LLP Says
5. Targets of Opportunity Still Hackers’ Best Friends, With Some New Twists, Mid-Year 2013 ENISA Report Shows
6. Significant US Peripheral Nerve Repair Market Opportunity Highlighted in New Independent Research
7. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
8. New “Autism Live” Parent 2 Parent Online Videos Provide Unique Opportunity to Share, Learn and Grow
9. Win the Opportunity to Meet Hall of Fame Golf Legend Nick Price
10. Personal Injury Lawyers Block O'Toole & Murphy, LLP See Serious Grand Central Parkway Car Accident as Opportunity to Educate Accident Victims
11. Diet Doc Now More Closely Tailors Its Medically Supervised Diet Plans Around Individual Patient Need, Providing an Opportunity to Live Longer & Feel Better Naturally
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
Breaking Medicine Technology: